Key facts
- Asylia Diagnostics’s last known valuation is $6.0M (Feb 2025).
- It has raised $1.7M.
- Notable investors include Johnson & Johnson Innovation - JLABS, Imec.istart, Davidovs Venture Collective, AstraZeneca, Az Alma — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Asylia Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Asylia Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Asylia Diagnostics
Developer of molecular diagnostics tests designed to provide safer immunotherapy for cancer patients. The company's approach is based on a transformative concept that leverages molecular and clinical RWE data and machine learning/AI, allowing de-risk upfront theranostic development, identifying non-responders to SoC, dissecting patient strata, and finding relevant biomarkers and novel targets to offer precision medicine systems for patients, enabling cancer patients to avail better and faster diagnosis.
- Sector
- Healthcare
- HQ
- Beerse, Belgium
- Founded
- 2019
- Employees
- 8
- Website
- asyliadx.com/
- Ownership
- Privately Held (backing)
Asylia Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Asylia Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Asylia Diagnostics in its N-PORT filings yet. We sweep new filings monthly.